These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8269594)

  • 1. Impact of omeprazole on the plasma clearance of methotrexate.
    Reid T; Yuen A; Catolico M; Carlson RW
    Cancer Chemother Pharmacol; 1993; 33(1):82-4. PubMed ID: 8269594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omeprazole does not alter plasma methotrexate clearance.
    Whelan J; Hoare D; Leonard P
    Cancer Chemother Pharmacol; 1999; 44(1):88-9. PubMed ID: 10367754
    [No Abstract]   [Full Text] [Related]  

  • 3. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma.
    Johansson ÅM; Hill N; Perisoglou M; Whelan J; Karlsson MO; Standing JF
    Ther Drug Monit; 2011 Dec; 33(6):711-8. PubMed ID: 22105588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose methotrexate in fibroblastic osteosarcoma.
    Chowbay B; Siong KK
    Ann Pharmacother; 2001 Dec; 35(12):1669. PubMed ID: 11793640
    [No Abstract]   [Full Text] [Related]  

  • 5. Methotrexate clearance and clinical toxicity in osteosarcoma following high-dose methotrexate therapy.
    Iqbal MP; Khursheed M; Mahboobali N
    J Pak Med Assoc; 1989 Feb; 39(2):38-42. PubMed ID: 2499702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Potential marker of the pharmacodynamic effect of high doses of methotrexate--homocysteine].
    Strizhevskaya AM; Senzhapova ER; Dzamraev AZ; Baykova VN
    Patol Fiziol Eksp Ter; 2014; (2):40-4. PubMed ID: 25318162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential interaction between methotrexate and omeprazole.
    Beorlegui B; Aldaz A; Ortega A; Aquerreta I; Sierrasesúmega L; Giráldez J
    Ann Pharmacother; 2000 Sep; 34(9):1024-7. PubMed ID: 10981249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma.
    Delepine N; Delepine G; Cornille H; Brion F; Arnaud P; Desbois JC
    Anticancer Res; 1995; 15(2):489-94. PubMed ID: 7763028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful rescue by oral cholestyramine of a patient with methotrexate nephrotoxicity: nonrenal excretion of serum methotrexate.
    Shinozaki T; Watanabe H; Tomidokoro R; Yamamoto K; Horiuchi R; Takagishi K
    Med Pediatr Oncol; 2000 Mar; 34(3):226-8. PubMed ID: 10696135
    [No Abstract]   [Full Text] [Related]  

  • 10. Appearance of a methotrexate binding plasma protein during high dose methotrexate therapy.
    Iqbal MP; Malik I; Mehboobali N
    J Pak Med Assoc; 1992 Aug; 42(8):193-6. PubMed ID: 1433799
    [No Abstract]   [Full Text] [Related]  

  • 11. [Determination of methotrexate concentration in serum: comparison between capillary and venous blood].
    Bömelburg T; Ritter J; Schellong G
    Klin Padiatr; 1987; 199(3):230-2. PubMed ID: 3476803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can primary osteosarcoma act as a third space after high-dose methotrexate?
    Bissett D; Kaye SB; Kerr DJ
    Eur J Cancer; 1991; 27(8):1060. PubMed ID: 1832895
    [No Abstract]   [Full Text] [Related]  

  • 13. Analytical interference in the therapeutic drug monitoring of methotrexate.
    Oudart JB; Marquet B; Feliu C; Gozalo C; Djerada Z; Millart H
    Ann Biol Clin (Paris); 2016 Jun; 74(3):333-7. PubMed ID: 27101631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serum methotrexate determination by microbiological assay in patients receiving high-dosage methotrexate (author's transl)].
    Krisch K; Kotz D; Mehta BM
    Wien Klin Wochenschr; 1977 Jul; 89(14):479-81. PubMed ID: 268729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate megadosage followed by folate rescue. I. A study in clearance patterns.
    Salasoo S; Irving MG; Lam-Po0Tang R; O'Gorman-Hughes D; Freedman A
    Med J Aust; 1976 May; 1(21):777-9. PubMed ID: 1085404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The influence of liver and renal functions on the changes in serum methotrexate (MTX) level in high-dose MTX therapy].
    Sato T; Nakanishi K; Takahashi M; Sato K; Miura T; Kuzuya T; Mizuno M
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2375-9. PubMed ID: 2260874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
    Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of peak serum methotrexate concentration to prognosis and drug tolerance in non-metastatic extremity osteosarcomas.
    Wang B; Yao H; Xie X; Yin J; Zou C; Huang G; Shen J
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):221-227. PubMed ID: 29808416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of 7-OH methotrexate metabolite on clinical relevance of methotrexate determination.
    Klapkova E; Kukacka J; Kotaska K; Suchanska I; Urinovska R; Prusa R
    Clin Lab; 2011; 57(7-8):599-606. PubMed ID: 21888024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma.
    Bacci G; Loro L; Longhi A; Bertoni F; Bacchini P; Versari M; Picci P; Serra M
    Anticancer Drugs; 2006 Apr; 17(4):411-5. PubMed ID: 16549998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.